Literature DB >> 10720633

Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor.

Y Nakamura1, T Haneda, J Osaki, S Miyata, K Kikuchi.   

Abstract

Primary cultures of neonatal cardiac myocytes were used to determine both the identity of second messengers that are involved in vasopressin receptor-mediated effects on cardiac hypertrophy and the type of vasopressin receptor that is involved in vasopressin-induced cell growth. Neonatal rat myocytes were plated at a density of 1x10(6) cells per 60 mm dish and were incubated with serum-free medium for 7 days. Treatment of myocytes with vasopressin significantly increased the RNA-to-DNA ratio, by 18-25%, at culture days 4-6 and the protein-to-DNA ratio by 18-20% at culture days 5-7. Rates of protein synthesis were determined to assess their contribution to protein contents during myocyte growth. Vasopressin significantly accelerated rates of protein synthesis by 25% at culture day 6. Intracellular free Ca(2+) ([Ca(2+)](i)) was transiently increased after vasopressin exposure. After the peak increase in [Ca(2+)](i) at less than 30 s, there was a sustained increase for at least 5 min. The specific activity of protein kinase C in the particulate fraction was increased rapidly after exposure to vasopressin, and its activity remained higher for 30 min, returning to its control level within 60 min. The activity of protein kinase C in the cytosol was significantly decreased at all times after exposure to vasopressin. After vasopressin treatment, the content of c-fos mRNA was increased. The stimulatory effects of vasopressin on these parameters were significantly inhibited by vasopressin V(1A) receptor antagonist, OPC-21268, but not by vasopressin V(2) receptor antagonist, OPC-31260. These results suggest that vasopressin directly induces myocyte hypertrophic growth via the V(1A) receptor in neonatal rat heart cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720633     DOI: 10.1016/s0014-2999(99)00775-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  27 in total

1.  A reduction in SK channels contributes to increased activity of hypothalamic magnocellular neurons during heart failure.

Authors:  Hildebrando C Ferreira-Neto; Vinicia C Biancardi; Javier E Stern
Journal:  J Physiol       Date:  2017-08-02       Impact factor: 5.182

2.  Enhanced NMDA receptor-mediated intracellular calcium signaling in magnocellular neurosecretory neurons in heart failure rats.

Authors:  Javier E Stern; Evgeniy S Potapenko
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-06-19       Impact factor: 3.619

Review 3.  Targeting hyponatremia and hemodynamics in acute decompensated heart failure: is there a role for vasopressin antagonists?

Authors:  Gregory Valania; Manmeet Singh; Mara T Slawsky
Journal:  Curr Heart Fail Rep       Date:  2011-09

4.  Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.

Authors:  Lisa C Costello-Boerrigter; William B Smith; Guido Boerrigter; John Ouyang; Christopher A Zimmer; Cesare Orlandi; John C Burnett
Journal:  Am J Physiol Renal Physiol       Date:  2005-09-27

5.  Oxytocin-Gly-Lys-Arg: a novel cardiomyogenic peptide.

Authors:  Bogdan A Danalache; Jolanta Gutkowska; Magdalena J Slusarz; Irena Berezowska; Marek Jankowski
Journal:  PLoS One       Date:  2010-10-26       Impact factor: 3.240

6.  Involvement of ERK and AKT signaling in the growth effect of arginine vasopressin on adult rat cardiac fibroblast and the modulation by simvastatin.

Authors:  Yan-Ping He; Lian-You Zhao; Qiang-Sun Zheng; Shao-Wei Liu; Xiao-Yan Zhao; Xiao-Long Lu; Xiao-Lin Niu; Xia Li
Journal:  Mol Cell Biochem       Date:  2008-06-26       Impact factor: 3.396

Review 7.  Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure.

Authors:  Navneet S Rehsia; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2010-01       Impact factor: 4.214

Review 8.  Vasopressin receptor antagonists: from pivotal trials to current practice.

Authors:  Ankur Kalra; Valmiki Maharaj; Steven R Goldsmith
Journal:  Curr Heart Fail Rep       Date:  2014-03

9.  Conivaptan and its role in the treatment of hyponatremia.

Authors:  Jalal K Ghali; Jareer O Farah; Suleiman Daifallah; Hassan A Zabalawi; Hammam D Zmily
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

10.  Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathy.

Authors:  Belinda S Cowling; Meagan J McGrath; Mai-Anh Nguyen; Denny L Cottle; Anthony J Kee; Susan Brown; Joachim Schessl; Yaqun Zou; Josephine Joya; Carsten G Bönnemann; Edna C Hardeman; Christina A Mitchell
Journal:  J Cell Biol       Date:  2008-12-15       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.